Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)

Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinder, Elizabeth M., Atwal, Gurprit S. S., Ayantunde, Abraham A., Khan, Sarah, Sokal, Mike, McCulloch, Tom, Parsons, Simon L.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2007
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225466/
https://www.ncbi.nlm.nih.gov/pubmed/18274611
http://dx.doi.org/10.1155/2007/82012
_version_ 1782149661628301312
author Pinder, Elizabeth M.
Atwal, Gurprit S. S.
Ayantunde, Abraham A.
Khan, Sarah
Sokal, Mike
McCulloch, Tom
Parsons, Simon L.
author_facet Pinder, Elizabeth M.
Atwal, Gurprit S. S.
Ayantunde, Abraham A.
Khan, Sarah
Sokal, Mike
McCulloch, Tom
Parsons, Simon L.
author_sort Pinder, Elizabeth M.
collection PubMed
description Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be considered in high risk groups. We report a case of TLS in a patient with metastatic gastrointestinal stromal tumour treated with imatinib mesylate. To our knowledge, this is the first reported case.
format Text
id pubmed-2225466
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-22254662008-02-14 Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571) Pinder, Elizabeth M. Atwal, Gurprit S. S. Ayantunde, Abraham A. Khan, Sarah Sokal, Mike McCulloch, Tom Parsons, Simon L. Sarcoma Case Report Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be considered in high risk groups. We report a case of TLS in a patient with metastatic gastrointestinal stromal tumour treated with imatinib mesylate. To our knowledge, this is the first reported case. Hindawi Publishing Corporation 2007 2007-11-20 /pmc/articles/PMC2225466/ /pubmed/18274611 http://dx.doi.org/10.1155/2007/82012 Text en Copyright © 2007 Elizabeth M. Pinder et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Pinder, Elizabeth M.
Atwal, Gurprit S. S.
Ayantunde, Abraham A.
Khan, Sarah
Sokal, Mike
McCulloch, Tom
Parsons, Simon L.
Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
title Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
title_full Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
title_fullStr Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
title_full_unstemmed Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
title_short Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
title_sort tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with glivec (imatinib mesylate, gleevec, sti571)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225466/
https://www.ncbi.nlm.nih.gov/pubmed/18274611
http://dx.doi.org/10.1155/2007/82012
work_keys_str_mv AT pinderelizabethm tumourlysissyndromeoccurringinapatientwithmetastaticgastrointestinalstromaltumourtreatedwithglivecimatinibmesylategleevecsti571
AT atwalgurpritss tumourlysissyndromeoccurringinapatientwithmetastaticgastrointestinalstromaltumourtreatedwithglivecimatinibmesylategleevecsti571
AT ayantundeabrahama tumourlysissyndromeoccurringinapatientwithmetastaticgastrointestinalstromaltumourtreatedwithglivecimatinibmesylategleevecsti571
AT khansarah tumourlysissyndromeoccurringinapatientwithmetastaticgastrointestinalstromaltumourtreatedwithglivecimatinibmesylategleevecsti571
AT sokalmike tumourlysissyndromeoccurringinapatientwithmetastaticgastrointestinalstromaltumourtreatedwithglivecimatinibmesylategleevecsti571
AT mccullochtom tumourlysissyndromeoccurringinapatientwithmetastaticgastrointestinalstromaltumourtreatedwithglivecimatinibmesylategleevecsti571
AT parsonssimonl tumourlysissyndromeoccurringinapatientwithmetastaticgastrointestinalstromaltumourtreatedwithglivecimatinibmesylategleevecsti571

Ejemplares similares